The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1699
April 1, 2024
View Complete Issue         Table of Contents 2019 
Omalizumab (Xolair) for Food Allergy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Omalizumab (Xolair) for Food Allergy
April 1, 2024 (Issue: 1699)
Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been approved for use in conjunction with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Omalizumab (Xolair) for Food Allergy
Article code: 1699b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.